ABSTRACT
The CCAAT/enhancer-binding protein-alpha (CEBPA) is a transcription factor strongly implicated in myelopoiesis through control of proliferation and differentiation of myeloid progenitors. Recently, several works have reported the presence of CEBPA-acquired mutations in hematological malignancies. In this work, we analyzed characteristics of mutations and their correlation with disease characteristics described in previous studies. In the 1175 patients reported, 146 CEBPA mutations were identified in 96 patients. Mutations were found in the whole gene sequence, but cluster regions were clearly identified. Furthermore, two categories of mutations were reported: out-of-frame ins/del often in the N-terminal region, and in-frame ins/del often in the C-terminal region. CEBPA mutations were reported exclusively in acute myeloid leukemia (AML) (according to WHO classification criteria) and mutated patients preferentially belonged to M1, M2 and M4 FAB subtypes. All but one case belonged to the 'intermediate' prognostic subgroup of MRC classification. In the absence of poor prognostic factors, patients with CEBPA mutation had favorable outcome, very similar to that of the t(8;21), inv(16), t(15;17) subgroup. Systematic analysis of CEBPA mutations, in addition to that of alterations in master genes of hematopoiesis, may be useful to assess the prognosis of AML particularly in patients belonging to the 'intermediate' prognostic subgroup.
Subject(s)
CCAAT-Enhancer-Binding Protein-alpha/genetics , Hematologic Neoplasms/genetics , Point Mutation/genetics , CCAAT-Enhancer-Binding Protein-alpha/physiology , Humans , PrognosisABSTRACT
25 Baerveldt glaucoma implants were placed in 22 patients, between 1992 and 1997. The indications were: 14 cases of neovascular glaucoma, 4 congenital glaucomas, 3 glaucomas due to intraocular silicone oil and 4 various glaucomas. The mean preoperative intraocular pressure was 46 mmHg (26-77) on a mean of 2.1 glaucoma medications. The postoperative mean intraocular pressure was 17 mmHg (5-50) on a mean of 0.5 glaucoma medications with a mean follow-up of 16 months (1 week-48 months). The final intraocular pressure was less than or equal to 20 mmHg in 20 of the 25 eyes. The final visual acuity improved or remained the same in 10 of the 25 cases and worsened in 11 cases (4 cases undetermined). The most frequently observed complications were: hyphema, choroidal effusion and corneal edema. Our results, in terms of intraocular pressure control, with the Baerveldt implant in patients with complicated glaucomas appear to be satisfactory. The use of this implant could be extended.
Subject(s)
Drainage/instrumentation , Glaucoma/surgery , Prosthesis Implantation , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle AgedABSTRACT
Vitreous surgery is often necessary to treat proliferative diabetic retinopathy. Sometimes cataract-extraction is indicated. A series of 37 eyes with ECCE, PC-IOL and vitrectomy in one operation is reviewed.
Subject(s)
Cataract Extraction/methods , Diabetic Retinopathy/surgery , Lenses, Intraocular , Vitrectomy/methods , Humans , Retinal Diseases/surgeryABSTRACT
Topical anesthesia with intravenous sedation was used in 100 cases of phacoemulsification. Results show that this technique is a good and safe alternative for retrobulbar and peribulbar anesthesia.
Subject(s)
Anesthesia, Local/methods , Phacoemulsification , Aged , Aged, 80 and over , Ambulatory Surgical Procedures , Anesthetics, Local , Conscious Sedation , Humans , Middle Aged , Procaine/analogs & derivativesSubject(s)
Arteriovenous Malformations , Eye Neoplasms , Fundus Oculi , Retinal Vessels , Angiomatosis/diagnosis , Angiomatosis/etiology , Angiomatosis/pathology , Arteriovenous Malformations/diagnosis , Arteriovenous Malformations/etiology , Arteriovenous Malformations/pathology , Choroid Neoplasms/pathology , Eye Neoplasms/diagnosis , Eye Neoplasms/etiology , Eye Neoplasms/pathology , Hemangioma/pathology , Humans , Neurofibromatosis 1/pathology , Optic Disk/blood supply , Retinal Diseases/diagnosis , Retinal Diseases/etiology , Retinal Diseases/pathology , Retinal Vessels/abnormalities , Retinal Vessels/pathologyABSTRACT
Trifluridine (TFT) and a structurally related analogue, 5-fluoro-2'-deoxyuridine (FDU), were investigated for their efficacy in the topical treatment of experimental keratitis caused by thymidine kinase-positive (TK+) and thymidine kinase-deficient (TK-) herpes simplex virus type 1 (HSV-1) strains. Bromovinyldeoxyuridine (BVDU) was used as a reference compound. Both 0.2% BVDU and 0.2% TFT eyedrops produced a highly significant healing of TK+HSV-1 keratitis as compared to the placebo and 0.2% FDU eyedrops (P much less than 0.005), whereas the latter compound did not differ from placebo eyedrops. In the treatment of TK HSV-1 keratitis, none of the drugs exhibited a beneficial healing effect, although the virus strain used was inhibited in vitro by TFT and FDU at a very low concentration (0.02-0.04 microgram/mL).
Subject(s)
Antiviral Agents/therapeutic use , Floxuridine/therapeutic use , Keratitis, Dendritic/enzymology , Thymidine Kinase/deficiency , Thymidine/analogs & derivatives , Trifluridine/therapeutic use , Animals , Bromodeoxyuridine/analogs & derivatives , Bromodeoxyuridine/therapeutic use , Drug Evaluation, Preclinical , Keratitis, Dendritic/drug therapy , RabbitsABSTRACT
A new acyclic adenosine analogue, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA], was evaluated for its efficacy in the topical treatment of experimental keratitis caused by the thymidine kinase-positive (TK+) and thymidine kinase-deficient (TK-) herpes simplex virus type 1 (HSV-1) strains. In the treatment of TK+ HSV-1 keratitis, 0.2% (S)-HPMPA eyedrops were as effective as the reference compounds, 0.2% (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and 0.2% 5-(2-chloroethyl)-2'-deoxy-uridine (CEDU) eyedrops. The three compounds produced a statistically significant healing effect, as compared with placebo eyedrops. In the treatment of keratitis caused by the TK- HSV-1 strain, 0.2%BVDU and 0.2% CEDU eyedrops did not differ from placebo eyedrops, whereas 0.2% (S)-HPMPA eyedrops exerted a highly significant healing effect.
